Under construction – not a live service
Sign in
Taking people in FrancePhase 3

Long-term study of ACP-204 for psychosis linked to Alzheimer's disease

Checks the long-term safety of ACP-204 in older adults with Alzheimer's psychosis.

Plain-language title generated from the registry record
Registry title: ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Key facts

Where
Bron, Colmar Cedex, Dijon, Limoges, Paris, Paris Cedex 10, Rouen, Toulouse, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy, and Villeurbanne, FranceSee the 12 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 95 years old?

Source: NCT06194799, who can take part

Where in France

  • Hospital Pierre WertheimerBron, FranceTaking people
  • Centre Hospitalier PasteurColmar Cedex, FranceTaking people
  • Centre Hospitalier Universitaire de DijonDijon, FranceTaking people
  • Centre Hospitalier Et Universitaire de LimogesLimoges, FranceTaking people
  • Assistance Publique Hopitaux de ParisParis, FranceTaking people
  • Assistance Publique Hopitaux De ParisParis Cedex 10, FranceTaking people
  • Centre Hospitalier Universitaire RouenRouen, FranceTaking people
  • Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people
  • Centre Hospitalier Universitaire De ToulouseToulouse Cedex 9, FranceTaking people
  • Centre Hospitalier Régional Universitaire de ToursTours, FranceTaking people
  • CHRU De NancyVandoeuvre Les Nancy, FranceTaking people
  • Hospices Civils De LyonVilleurbanne, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
ACADIA Pharmaceuticals Inc.
Trial code
NCT06194799EU 2023-507351-29-00
Record updated
4 November 2026
Original description
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.Read full original descriptionShow less

A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

Inclusion: Subject has successfully completed ACP-204-006 study; Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential; Subject has a designated study partner/caregiver; Subjects are able to complete all study visits with a study partner/caregiver; Signed inform consent form with a caregiver or legal representative.

Exclusion: Requires treatment with a medication prohibited by the protocol; Is in hospice and receiving end-of-life palliative care, or has become bedridden; Unstable clinically significant medical condition other than AD; Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study; Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.

ClinicalTrials.gov NCT06194799 · EU CTIS 2023-507351-29-00

Under construction, not live – ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study (NCT06194799) – Frontlight Research